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Abstract
Aim: The aim of this work was to evaluate the neutrophil
activation state in chronic kidney disease (CKD) patients un-
der hemodialysis, and its linkage with resistance to recombi-
nant human erythropoietin (rhEPO) therapy. Methods: We
studied 63 CKD patients under hemodialysis and rhEPO
treatment (32 responders and 31 non-responders to rhEPO
therapy). In 20 of the CIO patients (10 responders and 10
non-responders to rhEPO therapy), blood samples were also
collected immediately after dialysis. Twenty-six healthy vol-
unteers were included in a control group. Hemoglobin lev-
els, total and differential leukocyte counts, and circulating
levels of C-reactive protein (CRP), elastase and lactoferrin
were measured in all patients and controls. Results: Com-
pared with controls, CKD patients presented with signifi-
cantly higher CRP, neutrophil and elastase levels. When we
compared the 2 groups of patients, we found that non-
responders presented statistically significantly higher elas-
tase plasma levels. A positive significant correlation was
found between elastase levels and weekly rhEPO dose and
CRP serum levels. After the hemodialysis procedure, a statis-
tically significant rise in elastase, lactoferrin and, elastase/
neutrophil and lactoferrin/neutrophil ratios were found.
Conclusions: Our data show that CKD patients under hemo-
dialysis present higher elastase levels (particularly in non-
responding patients), which could be related to the rise in
neutrophils, and to be part of the enhanced inflammatory
process found in these patients.
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Introduction
Despite the technologic developments in hemodialysis
procedures and medical support over the last years, the
mortality and morbidity of chronic kidney disease (CKD)
patients under hemodialysis remains high, about 10-20
times higher than that found in the general population.
Anemia is the most frequent complication associated
with hemodialysis [1-31.
The management of anemia was improved by the in-
troduction of recombinant human erythropoietin (rhE-
PO) therapy, allowing a significant correction of anemia.
However, there is marked variability in the sensitivity to
rhEPO, with an up to 10-fold variability in dose require-
ments to achieve correction of anemia, and around 5-
10% of the patients showing a marked resistance to rhE-
PO therapy [4-61.
The interaction of blood with non-biological materials
of the extracorporeal circuit during hemodialysis leads to
the activation of several non-cellular. and cellular sys-
tems, including polymorphonuclear leukocytes (PMN)
[7, 8]. The activation of PMN may lead to degranulation,
with release of several components, namely, cationic pro-
teins and proteases and the production of oxygen me-
tabolites. Reports on this subject [7, 9, 10], though in a
limited number, have shown that neutrophils are acti-
vated during the hemodialysis procedure, but none of
those reports studied the relationship between resistance
to rhEPO therapy and neutrophil activation markers. Ac-
tually, it has been reported that rhEPO resistance seems
to be an associated inflammatory feature. Moreover,
none of those works calculated the ratios of neutrophil
activation products per number of neutrophils, a more
accurate measure of leukocyte activation.
The aim of this work was to evaluate the neutrophil
activation state in CKD patients under hemodialysis, and
its linkage with resistance to rhEPO therapy by measur-
ing circulating levels of elastase and lactoferrin. These
two substances are contained within primary and sec-
ondary neutrophil granules, respectively, and are fre-
quently used as indirect markers of neutrophil activation
in vivo.
Subjects and Methods
We performed a cross-sectional study by evaluating 63 CKD
patients under hemodialysis (36 males, 27 females; mean age ±
SD 62.1 ± 15.7 years) and rhEPO treatment. The CKD patients
included 32 responders and 31 non-responders to rhEPO therapy.
Classification of the patients as responders or non-responders was
performed in accordance with the European Best Practice Guide-
lines 1111 which defines resistance to rhEPO as failure to achieve
target hemoglobin levels (between 11 and 12 g/dl) with mainte-
nance doses of rhEPO of >300 113/kg/week of epoetin or 1.5 p.g/
kg/week of darbepoietin-a. The rhEPO maintenance dose for re-
sponding patients was 89.65 ± 57.62 U/kg/week and for non-re-
sponders 572.99 ± 193.84 U/kg/week. The 2 groups of patients
were matched for age (responders 62.3 ± 16.8 years vs. non-re-
sponders 62.9 ± 15.1 years, p > 0.05), gender (responders 56.25%
males vs. non-responders 58.06% males, p > 0.05), weight (re-
sponders 63.9 ± 11.7 kg vs. non-responders 58.6 ± 13.1 kg, p >
0.05), body mass index (responders 23.7 ± 3.4 vs. non-responders
21.8 ± 4.7, p> 0.05), mean time on hemodialysis (responders 68.0
± 65.7 months vs. non-responders 62.88 ± 51.2 months, p >
0.05), urea reduction ratio (responders 25.58 ± 7.71% vs. non-re-
sponders 27.8 ± 8.6%, p > 0.05), urea Ktv (responders 1.5 ± 0.3
vs. non-responders 1.63 ± 0.3, p > 0.05) and parathyroid hor-
mone serum levels (responders 294.5 ± 282.9 pg/mI vs. non-re-
sponders 282.2 ± 244.7 pg/ml, p > 0.05).
Twenty of the CKD patients (10 responders and 10 non-re-
sponders to rhEPO therapy) were also evaluated before and im-
mediately after hemodialysis.
CKD patients were under therapeutic hemodialysis three
times per week, for 3-5 h, for a median of 36 months. All patients
used the high-flux polysulfone FX-class dialyzers of Fresenius: 34
with FX60; 27 with FX80, and 2 with FX100 dialyzer type. The
causes of renal failure in the patient population were as follows:
diabetic nephropathy (n = 19); chronic glomerulonephritis (n =
10; polycystic kidney disease (n = 3); hypertensive nephrosclero-
sis = 3); obstructive nephropathy (n = 3); pyelonephritis associ-
ated with neurogenic bladder (n = 0; nephrolithiasis (n = 0;
chronic interstitial nephritis (n = 0; Alport syndrome (n = 1); re-
nal vascular disease due to polyarteritis (n = 1), and chronic renal
failure of uncertain etiology (n = 19). Patients with autoimmune
diseases, malignancy, hematological disorders, and acute or
chronic infection were excluded. Intravenous iron supplementa-
tion was based on the European Best Practice Guidelines for the
management of anemia in patients with hemodialysis [11]. All pa-
tients gave their informed consent to participate in this study.
Healthy volunteer were selected as controls based on normal
hematological and biochemical values, and no history of kidney
or inflammatory disease. They were also matched as far as pos-
sible for age and gender with the CKD patients (8 males, 17 fe-
males; mean ± SD age 47.81 ± 14.69 years).
Blood Sample Assays
Blood samples were collected with and without EDTA as an-
ticoagulant in order to obtain whole blood, serum and plasma. In
the cross-sectional study, blood samples were collected from CKD
patients before starting hemodialysis. To evaluate the effect of
hemodialysis in the parameters studied, blood samples were also
collected immediately after hemodialysis.
The hemoglobin concentration and white blood cell count
were measured using an automatic counter (Sysmex KI000, Ham-
burg, Germany) and leukocyte differential counts were evaluated
in Wright-stained blood films. Plasma levels of elastase and lac-
toferrin were evaluated by enzyme immunoassays (human PMN
Elastase ELISA, Bender MedSystems; Lactoferrin ELISA Kit, Cal-
biochem, respectively). Serum C-reactive protein (CRP) was de-
termined by immunoturbidimetry (CRP latex HS Roche kit,
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Table 1. Hematological data, iron status and neutrophil activation markers for controls and CKD patients
Controls (n = 26) All patients (n = 63) Responders (n = 32) Non-responders (n = 31)
Fib, g/d1 13.90 (13.2-15.00) 10.90 (10.30-12.30)' 11.70 (10.83-12.68)4 10.4 (9.00-11.30)' . b
White cell counts, x 109/1 5.78 ± 1.59 6.23 ± 2.10 6.42 ± 1.96 6.04 ± 2.26
Lymphocytes, x 109/1 2.35 ± 0.75 1.47 ± 0.604 1.58 ± 0.49' 1.36 ± 0.69°,6
Monocytes, x 109/1 0.25 ± 0.08 0.38 ± 0.164 0.40± 0.13' 0.35 ± 0.17'
Neutrophils, x 109/1 3.03 21.02 4.1421.79' 4.17 ± 1.87' 4.11 -± 1.73'
Ferritin, ng,/m1 85.10 (40.90-123.00) 383.80 (t88.20-546.25)6 399.00 (294.68-545.25)b 342.00 (163.00-580.05)b
Tranferrin saturation, % 19.44 (17.28-27.94) 21.80 (17.70-30.91) 24.20 (19.96-33.29) 22.10 (17.79-29.44)
Albumin, g/dI NM 3.8 ± 0.4 4.0 ± 0.4 3.7 ± a4b
CRP, mg/d1 1.75 (0.76-4.70) 5.75(1.90-14.01)' 3.20 (1.73-7.23)' 10.14 (3.82-38.99)'' b
Elastase, pg/I 28.29 (26.03-34.74) 36.11 (29.69-50.65)" 34.13(28.76-39.16)' 39.75 (31.15-64.84)"
Elastase/neutrophil ratio 10.86 (7.44-12.12) 8.91 (7.43-13.78) 8.70 (7.32-11.42) 10.25 (7.56-17.41)
Lactoferrin, u,g/1 236.56 (193.56-295.03) 239.35 (165.64-332.60) 239.60 (170.90-332.70) 228.90 (160.33-341.50)
Lactoferrin/neutrophil ratio 72.11 (55.52-111.83) 60.32 (42.82-99.45) 64.55 (44.31-101.49) 58.78 (41.50-102.99)
NM = Not made. Results are presented as mean ± standard deviation and as median (interquartile ranges).
p < 0.05 vs. controls; b p < 0.05 vs. responders.
Roche Diagnostics). Serum albumin levels were measured using
a calorimetric assay end-point method (Albumin Plus; Roche
GmbH, Mannheim, Germany). The serum iron concentration
was determined using a calorimetric method (Randox Laborato-
ries Ltd., Northern Ireland, UK), whereas serum ferritin (Randox
Laboratories Ltd.) and serum transferrin (Randox Laboratories
Ltd.) were measured by immunoturbidimetry. Transferrin satu-
ration (TS) was calculated using the formula: TS (96) = 70.9 x
serum iron concentration (ug/dI)/serum transferrin concentra-
tion (mg/dl).
Data Analysis
For statistical analysis, we used the Statistical Package for So-
cial Sciences (SPSS version 15.0 for Windows, SPSS Inc., Chicago,
Ill., USA). Kolmogorov Smirnov statistics were used to evaluate
sample normality distribution. Multiple comparisons between
groups were performed by one-way ANOVA supplemented with
Turkey's HSD post hoc test. For single comparisons, we used the
Student's t test whenever the parameters presented a Gaussian
distribution and the Mann-Whitney U test in the case of a non-
Gaussian distribution. To compare data before and after hemodi-
alysis, we used paired-samples t test or Wilcoxon test. Spearman's
rank correlation coefficient was used to evaluate relationships be-
tween sets of data. Significance was accepted at p < 0.05.
Results
The hematological characteristics, iron status and the
inflammatory markers of the 3 groups studied (cross-
sectional study) are summarized in table 1. Hemodialysis
CKD patients were anemic, with non-responding pa-
tients being more anemic than responders. No difference
was found between controls and patients concerning the
white blood cell count. However, CKD patients showed
lymphopenia, as well as higher monocyte and neutrophil
counts as compared to controls. When comparing the 2
groups of patients, non-responders presented a signifi-
cantly lower lymphocyte count than responders.
Compared with controls, CKD patients presented sig-
nificantly higher ferritin, CRP and elastase plasma levels
(table 2). However, no statistically significant differences
were found for the elastase/neutrophil ratio. No statisti-
cally significant differences were also found between
CKD patients and controls for plasma levels of lactoferrin
and lactoferrin/neutrophil ratio. When we compared the
2 groups of patients, we found that non-responders
showed decreased serum levels of albumin, and higher
CRP and elastase plasma levels. Statistically significantly
positive correlations were found between elastase plasma
levels and weekly rhEPO dose and CRP (fig. 1).
Analyzing the results for hematological data, and for
neutrophil activation markers, before and immediately
after the hemodialysis procedure (table 2), we found a sta-
tistically significant rise in hemoglobin, elastase, lacto-
ferrin and, elastase/neutrophil and lactoferrin/neutro-
phil ratios. No statistically significant changes were found
between responders and non-responders for any of the
parameters studied.
Discussion
As far as we know, we are the first group to assess the
association between neutrophil activation and resistance
to rhEPO therapy in CKD patients under hemodialysis.
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Hemodialysis patients (n = 20)
before after
Hb, g/dI 12.10 (10.95-12.80) 13.20 (11.15-14.60)'
White cell counts, x 109/1 5.86± 1.51 5.93 ± 2.19
Neutrophils, x 109/I 3.82 ± 1.24 3.97± 1.77
Monocytes, X 109/1 0.24 ± 0.38 0.17 ± 0.12
Lymphocytes, x 109/1 1.64 + 0.69 1.66 ± 0.64
Elastase, pig/I 36.16 (29.71-47.13) 51.69 (40.08-71.68)'
Elastase/neutrophil ratio 10.66 (7.32-13.54) 14.66 (13.34-18.95)a
Lactoferrin, pg/I 198.61 (137.81-216.97) 236.56 (171.28-363.63)'
Lactoferrin/neutrophil ratio 48.33 (33.88-64.31) 60.72 (51.81-94.81)'
CRP, mg/di 3.06 (1.39-5.22) 3.53 (1.54-5.56)
Results are presented as mean ± standard deviation and as median (interquartile
ranges). p < 0.05 vs. before hemodialysis.
Table 2. Hematological data and
neutrophil activation markers for
CKD patients, before and after the
hemodialysis procedure
We were able to demonstrate that elastase, a neutrophil
protease released by degranulation, is significantly high-
er in the plasma of CKD patients under hemodialysis, be-
ing particularly high in non-responding CKD patients.
This is probably part of the enhanced inflammatory sta-
tus reported for these CKD patients.
In the cross-sectional study, performed before hemo-
dialysis, we assessed chronic inflammation associated
with CKD and with resistance to rhEPO therapy. We
found that CKD patients under hemodialysis treatment
show a significant rise in neutrophils and increased CRP
levels in serum, confirming the presence of an inflamma-
tory process in these patients. The fact that non-respond-
ers had higher CRP levels suggests that inflammation is
related to resistance to rhEPO therapy, in agreement with
previous studies [12, 13]. The lymphopenia found in he-
modialysis patients is particularly enhanced in non-re-
sponders. This feature has already been described in the
literature [13] and results, at least in part, from a decrease
in total circulating CD3+ T lymphocytes and affects both
the CD4+ and the CD8+ T-cell subsets.
We used lactoferrin and elastase plasma levels as neu-
trophil activation markers. Elastase levels were signifi-
cantly higher in hemodialysis patients, particularly in
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Fig.1. Correlation between plasma elastase levels and weekly rhEPO dose (a) and CRP (b) in hemodialysis patients.
non-responding patients. However, no statistical differ-
ences were found for the elastase/neutrophil ratio be-
tween controls and patient groups, suggesting that the
higher elastase levels are mainly associated with the in-
creased neutrophil count found in these patients. Even so,
it is important to highlight that the elastase/neutrophil
ratio presented a trend to higher values in non-respond-
ers. Moreover, we found statistically significant positive
correlations between elastase levels and CRP, suggesting
that the rise in elastase levels is part of the inflammatory
process found in hemodialysis patients and particularly
enhanced in non-responders. The statistically significant
correlation between elastase levels and weekly rhEPO
doses also corroborate this hypothesis; in fact, non-re-
sponders to rhEPO therapy who require higher weekly
rhEPO doses to achieve target hemoglobin levels are also
associated with an increased inflammatory process.
On the other hand, plasma levels of lactoferrin and the
lactoferrin/neutrophil ratio did not differ between groups.
A plausible justification for this result is that, although
the major circulating lactoferrin is neutrophil-derived, it
may also be produced by other cells [15]. Contrary to the
evaluation of elastase, the ELISA kit used is not specific
for the evaluation of PMN leukocyte lactoferrin levels.
Thus, in our study, elastase is a more specific marker of
neutrophil activation. Moreover, we can also consider the
hypothesis that lactoferrin is being used or cleared from
the circulation in a pronounced way. Indeed, lactoferrin
is involved in iron metabolism, which is known to be al-
tered in these patients [16].
By evaluating CKD patients before and after hemodi-
alysis, we assessed whether our patients respond in same
manner to the hemodialysis process. After hemodialysis,
a higher hemoglobin level was found, and has been at-
tributed to a translocation of erythrocytes from the
splanchnic circulation (and possibly from the spleen) in
order to compensate for the hypovolemic stress during
dialysis ultrafiltration [17, 18]. After hemodialysis we also
found a statistically significant increase in both elastase
and lactoferrin concentrations (and in their ratios per
neutrophil), suggesting a neutrophilic activation process
with degranulation during the hemodialysis procedure.
We also found that neutrophils from non-responding pa-
tients to rhEPO therapy do not respond any differently
than those found in responding patients. It is likely that
the higher elastase levels found in non-responders (cross-
sectional study) is likely to result from a chronic but not
acute stimulus of the hemodialysis process.
In conclusion, our data show that CKD patients under
hemodialysis present higher elastase levels (particularly
in non-responding patients), which could be related to
the rise in neutrophils and could be part of the enhanced
inflammatory process found in these patients. Moreover,
neutrophil activation is triggered by the hemodialysis
procedure, but does not explain the higher elastase levels
found in non-responding patients. Elastase, but not lac-
toferrin, may prove to be a good marker of resistance to
rhEPO therapy in CKD patients under hemodialysis.
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